ASP Isotopes Inc. Expects First Commercial Shipments and Helium Phase 1 Capacity in 2026; Targets $300M+ EBITDA by 2031

ASP Isotopes Inc. Issues Major Business Update with Key Milestones and Financial Targets

First Commercial Shipments Expected Across Multiple Isotopes in 2026; Helium Phase 1 Nameplate Capacity Expected in Q3 2026; \$300M+ EBITDA Target for 2031

Key Highlights

First Commercial Shipments: ASP Isotopes (NASDAQ: ASPI) expects to commence commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176 in 2026.
Helium Project Progress: The company expects to achieve Phase 1 nameplate capacity for helium production at the Virginia Gas Project in Q3 2026, ahead of previous schedules.
Strong Financial Position: As of December 31, 2025, ASP Isotopes holds \$333 million in cash, cash equivalents, and marketable securities.
Ambitious Profitability Target: The company is targeting EBITDA of greater than \$300 million by 2031.
Significant U.S. Expansion: Acquisition of two U.S. radiopharmacies, with plans for further expansion.
Renergen Limited Acquisition: Closed acquisition of Renergen Limited and accelerated the timeline for helium production.
Quantum Leap Energy (QLE) Progress: Preparation for public listing, new strategic contracts, and leadership appointments.
Substantial Capital Raised: Over \$345 million raised in 2025 via stock issuances and convertible notes.

Detailed Business Update

ASP Isotopes Inc., a leader in advanced isotope enrichment technologies, delivered a comprehensive business update that signals a pivotal year ahead for the company. CEO Paul Mann emphasized that 2026 will be a transformative period as ASP Isotopes brings its enrichment technology to commercial scale for the first time.

Nuclear Medicine

Ytterbium-176 (Yb-176):
- The company shipped its first enriched Yb-176 sample to a prospective customer in August 2025. Yb-176 is a critical precursor for Lutetium-177, a key isotope for targeted radionuclide therapy for neuroendocrine tumors and prostate cancer.
- Production experienced a temporary halt in October 2025 due to a power surge in Pretoria, South Africa, which damaged a laser. The issue was resolved, and production resumed.
- Initial commercial shipments of Yb-176 are targeted for mid to Q3 2026.
Carbon-14:
- ASP Isotopes entered a multi-year supply agreement with a Canadian customer in June 2023, with a minimum commitment of approximately \$2.5 million per year.
- The enrichment facility has been operating for over two years, building operational stability while waiting for final feedstock from the customer, which is expected imminently.
- Commercial shipments of Carbon-14 are anticipated around mid-2026, pending feedstock delivery.
Radiopharmaceuticals (PET Labs):
- PET Labs, 51%-owned by ASP Isotopes, continues strong operational progress in South Africa, with two cyclotrons now operational and meeting record demand.
- U.S. expansion includes the acquisition of radiopharmacies in Florida and South Carolina (current SPECT, PET capability coming in 2027 and 2028, respectively).
- Targeting \$10 million+ in revenue from radiopharmacies in 2026, doubling 2025 revenue.

Electronics

Silicon-28 (Si-28):
- Three purchase agreements signed for highly enriched Si-28, including with a major U.S. semiconductor company and a global industrial gases company.
- First enriched Si-28 samples shipped in August 2025; independent analysis confirmed enrichment levels as expected.
- First commercial shipments expected in Q2 2026.

Helium and LNG: Virginia Gas Project

Acquisition of Renergen Limited closed January 2026.
Phase 1 drilling completed four months ahead of schedule; wells show flow rates up to 16x higher than earlier estimates.
Phase 1 nameplate capacity: 2,500 GJ/day of LNG and 58 MCF/day of liquid helium, expected Q3 2026.
Phase 2 (44-month construction): 34,000 GJ/day of LNG and 895 MCF/day of helium.
Active negotiations underway with potential customers for product offtake.

Nuclear Fuels: Quantum Leap Energy (QLE)

Confidential S-1 registration submitted to the SEC in November 2025 for planned public listing.
Service contract signed with NECSA for access to the Pelindaba nuclear site in South Africa for uranium enrichment R&D.
Austin, Texas named as global HQ in February 2026.
Dr. Nate Salpeter (ex-TerraPower, Kairos Power) appointed as CTO in March 2026.
MoU signed with a large U.S. energy company to advance domestic enriched uranium fuel supply chain.

Financial Highlights

Cash Position: \$333 million in cash, equivalents, and marketable securities as of December 31, 2025.
Capital Raised: \$345 million raised in 2025, including a \$199.7 million stock issuance and \$42.2 million in QLE convertible notes.
Product Revenue: \$5.7 million for 2025, up 46% from \$3.9 million in 2024, driven by U.S. radiopharmacy expansion.
Net Loss: \$175.1 million for 2025, compared to \$32.3 million in 2024, reflecting heavy investment in growth and expansion.
EBITDA Target: Expects to achieve EBITDA >\$300 million by 2031.

Important Shareholder Information & Price-Sensitive Items

2026 will be the first year of commercial shipments for multiple isotopes, representing a significant revenue inflection point and validation of ASP Isotopes’ technology.
The completion of the Renergen acquisition and accelerated helium production timeline could unlock substantial new revenue streams and position the company as a major helium supplier.
Progress in the public listing of Quantum Leap Energy, strategic partnerships, and U.S. expansion signal further upside and de-risking of the business model.
Substantial capital raised and a strong cash position mitigate financing risk for upcoming projects and expansion.
An ambitious long-term EBITDA target (\$300M+ by 2031) provides a clear milestone for investors, but also comes with forward-looking statement caveats and risks.
Significant increase in net loss reflects aggressive investment, but may impact near-term profitability metrics and investor sentiment.

Upcoming Catalysts

Initial commercial shipments of Yb-176, Carbon-14, and Si-28 in 2026.
Helium Phase 1 nameplate capacity achievement in Q3 2026.
Further radiopharmacy acquisitions and U.S. expansion.
Progress toward a public listing for Quantum Leap Energy.

Conference Call Information

ASP Isotopes will host a business update conference call on April 13, 2026, at 8:00 AM ET. A replay will be available at www.aspisotopes.com approximately three hours after the call.

About ASP Isotopes Inc.

ASP Isotopes is an advanced materials company specializing in differentiated isotope enrichment platforms supporting the nuclear medicine, semiconductor, and nuclear energy industries. Their proprietary Aerodynamic Separation Process and Quantum Enrichment technologies drive their operations in Pretoria, South Africa, with a focus on light isotopes and global supply chain security.

Disclaimer

This article contains forward-looking statements based on current expectations, plans, and projections of ASP Isotopes Inc. regarding future operations, performance, and business prospects. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Shareholders and potential investors are cautioned not to place undue reliance on these statements. This summary does not constitute investment advice. Please refer to ASP Isotopes’ official filings and disclosures for further details. The author of this article does not hold any position in ASP Isotopes at the time of writing.